Key result
Oral factor Xa inhibitors show no difference in 3-month VTE recurrence versus warfarin and enoxaparin.
Why the study?
Studies are needed to compare oral factor Xa inhibitors, low molecular weight heparins, and warfarin for secondary prevention of venous thromboembolism in oncology patients.
Do oral factor Xa inhibitors (rivaroxaban/apixaban) prevent recurrent venous thromboembolism compared to enoxaparin or warfarin in oncology patients with active cancer and VTE?
Cohort (n=127)
Do oral factor Xa inhibitors (rivaroxaban/apixaban) prevent recurrent venous thromboembolism compared to enoxaparin or warfarin in oncology patients with active cancer and VTE?
Oral factor Xa inhibitors appear to be a potential option for preventing recurrent venous thromboembolism in cancer patients, with similar efficacy to warfarin and enoxaparin at three months.
Answers are grounded in this paper and cite their sources.
Oral factor Xa inhibitors may be explored in cancer-associated VTE; leaves open confirmation versus warfarin or enoxaparin in randomized trials.
Background There is increasing evidence indicating oral factor Xa inhibitors can be used for secondary prevention of venous thromboembolism. Studies are needed to compare oral factor Xa inhibitors, low molecular weight heparins, and warfarin in the oncology population. The purpose of this study is to evaluate the recurrent venous thromboembolism incidence in oncology patients utilizing oral Xa inhibitors, low molecular weight heparins, or warfarin. Methods Using retrospectively collected data, we compared the recurrent venous thromboembolism incidence in oncology patients taking rivaroxaban/apixaban, enoxaparin, or warfarin with at least three months of follow-up. Patients were included if they had an active cancer, venous thromboembolism, and taking warfarin, enoxaparin, or rivaroxaban/apixaban. The primary endpoint was the first episode of recurrent venous thromboembolism at three months. Secondary endpoints included recurrent venous thromboembolism after six months, major bleeding, and mortality. Results Of 127 venous thromboembolism patients, 48 received rivaroxaban or apixaban, 23 received enoxaparin, and 56 received warfarin. The three most common cancer diagnoses were lung (21%), colorectal (14%), and breast (14%). There was no difference in venous thromboembolism recurrence at three months between the rivaroxaban/apixaban (0%), warfarin (3.6%), and the enoxaparin cohorts (4.4%) (p = 0.8319). Major bleeding at three months was only seen in one patient in the enoxaparin arm (4.2%). Mortality at three months was 0%, 3.6%, and 17.4% in the rivaroxaban/apixaban, warfarin, and enoxaparin cohorts, respectively. Conclusion The results of this retrospective study suggest that oral factor Xa inhibitors are potential options for cancer patients with venous thromboembolism. However, randomized, controlled trials are needed to confirm these results.
No takes yet. Share an insight, caveat, or question.
Alzghari et al. (2017) conducted a cohort in Venous thromboembolism in oncology patients (n=127). Oral factor Xa inhibitors (rivaroxaban/apixaban) vs. Warfarin and enoxaparin was evaluated on First episode of recurrent venous thromboembolism at three months (p=0.8319). Oral factor Xa inhibitors showed no significant difference in 3-month VTE recurrence compared to warfarin and enoxaparin in oncology patients.
Synapse has enriched 10 related papers. Consider them for comparative context: